

*Evolut	
Clinical Guidelines STRESS ECHOCARDIOGRAPHY	Original Date: February 2010
CPT Codes: 93350, 93351, +93320, +93321, +93325, +93352, +93356	Last Revised Date: May 2023
Guideline Number: Evolut_CG_026	Implementation Date: January 2024

GENERAL INFORMATION

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

This guideline is for stress imaging, specifically Stress Echocardiography (SE) with appropriate preference for suitable alternatives, such as an exercise treadmill exam without imaging, when more suitable, unless otherwise stated (refer to [Overview section](#)).

INDICATIONS for STRES ECHO ¹⁻³

SUSPECTED CORONARY ARTERY DISEASE (CAD)

Symptomatic patients without known CAD (use [Diamond Forrester Table](#))

- Low or intermediate pretest probability, and electrocardiogram (ECG) is uninterpretable
- High pretest probability
- Repeat testing in patient with new or worsening symptoms and negative result at least one year ago AND meets one of the criteria above

Asymptomatic patients without known CAD

- Previously unevaluated ECG evidence of possible myocardial ischemia including ischemic ST segment or T wave abnormalities ([see Overview section](#))
- Previously unevaluated pathologic Q waves ([see Overview section](#))
- Previously unevaluated complete left bundle branch block

ABNORMAL CALCIUM SCORES (CAC)^{1, 4-7}

- ASYMPTOMATIC patient with a calcium score >400, not previously evaluated
- SYMPTOMATIC patient with prior CAC \geq 100

INCONCLUSIVE CAD EVALUATION AND OBSTRUCTIVE CAD REMAINS A CONCERN

- Exercise stress ECG with low-risk Duke treadmill score \geq 5, but patient's current symptoms indicate an intermediate or high pretest probability
- Exercise stress ECG with an intermediate Duke treadmill score
- Intermediate coronary computed tomography angiography (CCTA) defined as:
 - 40 -70% lesion
- Coronary stenosis of unclear significance on previous coronary angiography¹

FOLLOW-UP OF PATIENTS POST CORONARY REVASCULARIZATION (PCI or CABG)⁸

- **Asymptomatic, follow-up stress imaging** (MPI or SE), at a minimum of 2 years post coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI), whichever is later, is appropriate for patients with a history of silent ischemia or a history of a prior left main stent¹

OR

- For patients with high occupational risk including any of the following:
 - Associated with public safety
 - Airline and boat pilots
 - Bus and train drivers
 - Bridge and tunnel workers/toll collectors
 - Police officers and firefighters
- **New, recurrent, or worsening symptoms post coronary revascularization** is an indication for stress imaging

FOLLOW-UP OF KNOWN CAD

- **Routine follow-up of asymptomatic or stable symptoms** when last invasive or non-invasive assessment of coronary disease showed hemodynamically significant CAD (ischemia on stress test or FFR \leq 0.80 or significant stenosis in a major vessel (\geq 50% left main coronary artery or \geq 70% LAD, LCX, RCA)), over two years ago without intervening coronary revascularization, is an appropriate indication for stress imaging (MPI or SE)

SPECIAL DIAGNOSTIC CONDITIONS REQUIRING CORONARY EVALUATION

- Prior acute coronary syndrome (with documentation in MD notes), within last three months, without a prior stress test or coronary angiography performed since that time

- Newly diagnosed systolic heart failure or diastolic heart failure, **with reasonable suspicion of cardiac ischemia (prior events, risk factors)**, unless invasive coronary angiography is immediately planned^{4, 8}
- Ventricular arrhythmias:
 - Sustained ventricular tachycardia (VT) > 100 bpm, ventricular fibrillation (VF), or exercise-induced VT, when invasive coronary arteriography has not been performed⁹
 - Nonsustained VT, multiple episodes, each ≥ 3 beats at ≥ 100 bpm, frequent PVCs (defined as greater than or equal to 30/hour on remote monitoring), when an exercise ECG cannot be performed⁹
- For intermediate and high-risk global patients who require initiation of Class IC antiarrhythmic drugs. It can be performed annually thereafter until discontinuation of drug use¹⁰
- Hemodynamic assessment of ischemia in one of the following documented conditions:
 - Anomalous coronary arteries in an asymptomatic individual without prior stress echocardiography¹¹;
 - Myocardial bridging of a coronary artery¹²
- Coronary aneurysms in Kawasaki's disease¹³
- Following radiation therapy to the anterior or left chest, at 5 years post initiation and every 5 years thereafter¹⁴

CHRONIC VALVULAR DISEASE

Evaluation with Inclusion of Doppler¹⁵⁻¹⁸

- For the evaluation of aortic stenosis and flow (contractile) reserve in symptomatic patients with severe aortic stenosis by calculated valve area, low flow / low gradient, and ejection fraction < 50%
- For evaluation of asymptomatic moderate or severe aortic stenosis (AS) for measurement of changes in valve hemodynamics
- Non-severe aortic regurgitation (AR) with symptoms: Assessment of functional capacity and to assess for other causes of symptoms^{8, 19}
- For evaluation of mitral stenosis (MS) if there is:
 - Exertional shortness of breath which suggests the amount of MS is worse than is seen on the resting echocardiogram
- For evaluation for mitral regurgitation (MR) if there is:
 - Exertional shortness of breath which suggests the amount of MR is worse than is seen on the resting echocardiogram; **OR**
 - The echocardiogram is not able to distinguish whether the MR is moderate or severe in a patient that is asymptomatic

- For symptomatic patients with HCM, who do not have resting or provokable outflow tract gradient ≥ 50 mm Hg on TTE, for detection and quantification of dynamic LVOT obstruction²⁰
- For asymptomatic patients with HCM who do not have a resting or provokable outflow tract gradient ≥ 50 mm Hg on TTE (Class 2A)

DIASTOLIC FUNCTION

- For unexplained dyspnea and suspected heart failure with preserved LVEF¹⁹ (HFpEF) with normal or equivocal diastolic function on resting images

PRIOR TO ELECTIVE NON-CARDIAC SURGERY^{2, 21-23}

- An intermediate or high risk surgery with of one or more risk factors (see below), AND documentation of an inability to walk (or <4 METs) **AND** there has not been an imaging stress test within 1 year^{21, 23, 24}
 - **Risk factors:** history of ischemic heart disease, history of congestive heart failure, history of cerebrovascular disease, preoperative treatment with insulin, and preoperative serum creatinine >2.0 mg/dL.
 - **Surgical Risks:**
 - **High risk surgery:** Aortic and other major vascular surgery, peripheral vascular surgery, anticipated prolonged surgical procedures associated with large fluid shifts and/or blood loss
 - **Intermediate risk surgery:** Carotid endarterectomy, head and neck surgery, intraperitoneal and intrathoracic surgery, orthopedic surgery, prostate surgery
 - **Low risk surgery:** Endoscopic procedures, superficial procedure, cataract surgery, breast surgery
- Planning for any organ or stem cell transplantation is an indication for preoperative stress imaging, if there has not been a conclusive stress evaluation, CTA, or heart catheterization within the past year, at the discretion of the transplant service.^{2, 25}

POST CARDIAC TRANSPLANTATION

- Annually, for the first five years post cardiac transplantation, in a patient not undergoing invasive coronary arteriography
- After the first five years post cardiac transplantation, patients with documented transplant coronary vasculopathy can be screened annually unless invasive coronary arteriography is planned

BACKGROUND

Stress echocardiography (SE) refers to ultrasound imaging of the heart during exercise electrocardiography (ECG) testing, during which visualized wall motion abnormalities can provide evidence of potential significant coronary artery disease (CAD).

While drug-induced stress with dobutamine can be an alternative to exercise stress testing in patients who are unable to exercise, this guideline does not require use of this modality. Hence, reference in this document to SE predominantly refers to exercise stress echocardiography.

Although SE provides comparable accuracy without radiation risk, relative to myocardial perfusion imaging (MPI), scenarios which do not permit effective use of SE might be better suited for stress imaging with MPI, cardiovascular magnetic resonance imaging (CMR) or positron emission tomography (PET), or coronary computed tomography angiography (CCTA).

Stable patients without known CAD fall into 2 categories¹⁻³:

- **Asymptomatic patients**, for whom Global Risk of CAD events can be determined from coronary risk factors using calculators available online (see Websites for [Global Cardiovascular Risk Calculators](#) section)
- **Symptomatic patients**, for whom we estimate the Pretest Probability that their chest-related symptoms are due to clinically significant CAD (see below):

The 3 Types of Chest Pain or Discomfort:

- **Typical Angina (Definite)** is defined as including **all 3** of these characteristics:
 - Substernal chest pain or discomfort with characteristic quality and duration, such as:
 - Pressure-like
 - Radiating
 - Dull or aching
 - Provoked by exertion or emotional stress
 - Relieved by rest and/or nitroglycerine
- **Atypical Angina (Probable)** has only **2** of the above characteristics
- **Nonanginal Chest Pain/Discomfort** has only **0-1** of the above characteristics

The medical record should provide enough detail to establish the type of chest pain. From those details, the Pretest Probability of obstructive CAD is estimated from the [Diamond Forrester Table](#) below, recognizing that in some cases multiple additional coronary risk factors could increase pretest probability^{1,3}:

Diamond Forrester Table

Age (Years)	Gender	Typical/Definite Angina Pectoris	Atypical/Probable Angina Pectoris	Nonanginal Chest Pain
≤ 39	Men	Intermediate	Intermediate	Low
	Women	Intermediate	Very low	Very low
40 – 49	Men	High	Intermediate	Intermediate
	Women	Intermediate	Low	Very low
50 – 59	Men	High	Intermediate	Intermediate
	Women	Intermediate	Intermediate	Low
≥ 60	Men	High	Intermediate	Intermediate
	Women	High	Intermediate	Intermediate

- **Very low:** < 5% pretest probability of CAD, usually not requiring stress evaluation³
- **Low:** 5 - 10% pretest probability of CAD
- **Intermediate:** 10% - 90% pretest probability of CAD
- **High:** > 90% pretest probability of CAD

OVERVIEW

MPI may be performed without diversion to SE in any of the following^{1, 26}:

- Inability to exercise
 - Physical limitations precluding ability to exercise for at least 3 full minutes of Bruce protocol
 - Limited functional capacity (< 4 metabolic equivalents) **such as one** of the following:
 - Cannot take care of their activities of daily living (ADLs) or ambulate
 - Cannot walk 2 blocks on level ground
 - Cannot climb 1 flight of stairs
 - Cannot vacuum, dust, do dishes, sweep, or carry a small grocery bag
- Other Comorbidities
 - Severe chronic obstructive pulmonary disease with pulmonary function test (PFT) documentation, severe shortness of breath on minimal exertion, or requirement of home oxygen during the day
 - Poorly controlled hypertension, with systolic BP > 180 or Diastolic BP > 120 (and clinical urgency not to delay MPI)
- ECG and Echo-Related Baseline Findings
 - Prior cardiac surgery (coronary artery bypass graft or valvular)
 - Documented poor acoustic imaging window
 - Left ventricular ejection fraction ≤ 40%
 - Pacemaker or ICD
 - Persistent atrial fibrillation
 - Resting wall motion abnormalities that would make SE interpretation difficult

- Complete LBBB
- Risk-related scenarios
 - High pretest probability in suspected CAD
 - Intermediate or high global risk in patients requiring type IC antiarrhythmic drugs (prior to initiation of therapy and annually)
 - Arrhythmia risk with exercise
- Previously unevaluated pathologic Q waves (in two contiguous leads) defined as the following:
 - > 40 ms (1 mm) wide
 - > 2 mm deep
 - > 25% of depth of QRS complex

ECG Stress Test Alone versus Stress Testing with Imaging

Prominent scenarios suitable for an ECG stress test **WITHOUT** imaging (i.e., exercise treadmill ECG test) are inferred from the guidelines presented above, often requiring that the patient can exercise for at least 3 minutes of Bruce protocol with achievement of near maximal heart rate **AND** has an interpretable ECG for ischemia during exercise¹:

- The (symptomatic) low or intermediate pretest probability patient who is able to exercise and has an interpretable ECG
- The patient who is under evaluation for exercise-induced arrhythmia⁹
- For the evaluation of syncope or presyncope during exertion²⁷
- The patient who requires an entrance stress test ECG for a cardiac rehab program or for an exercise prescription.

Duke Exercise ECG Treadmill Score²⁸

Calculates risk from ECG treadmill alone:

- The equation for calculating the Duke treadmill score (DTS) is: $DTS = \text{exercise time in minutes} - (5 \times \text{ST deviation in mm or } 0.1 \text{ mV increments}) - (4 \times \text{exercise angina score})$, with angina score being 0 = none, 1 = non-limiting, and 2 = exercise-limiting.
- The score typically ranges from - 25 to + 15. These values correspond to low-risk (with a score of $\geq + 5$), intermediate risk (with scores ranging from - 10 to + 4), and high-risk (with a score of ≤ -11) categories.

An uninterpretable baseline ECG includes³:

- ST segment depression 1 mm or more; (not for non-specific ST- T wave changes)
- Ischemic looking T wave -- at least 2.5 mm inversions (excluding V1 and V2)
- LVH, pre-excitation pattern such as WPW, a ventricular paced rhythm, or left bundle branch block
- Digitalis use

- Resting HR under 50 bpm on a medication, such as beta-blockers or calcium channel blockers, that is required for patient’s treatment and cannot be stopped, with an anticipated suboptimal workload

Global Risk of Cardiovascular Disease

Global risk of CAD is defined as the probability of manifesting cardiovascular disease over the next 10 years and refers to **asymptomatic** patients without known cardiovascular disease. It should be determined using one of the risk calculators below. A high risk is considered greater than a 20% risk of a cardiovascular event over the ensuing 10 years. High global risk by itself generally lacks scientific support as an indication for stress imaging. There are rare exemptions, such as patients requiring IC antiarrhythmic drugs, who might require coronary risk stratification prior to initiation of the drug.

- **CAD Risk—Low**
10-year absolute coronary or cardiovascular risk less than 10%.
- **CAD Risk—Moderate**
10-year absolute coronary or cardiovascular risk between 10% and 20%.
- **CAD Risk—High**
10-year absolute coronary or cardiovascular risk of greater than 20%.

Websites for Global Cardiovascular Risk Calculators*

Risk Calculator	Link to Online Calculator
Framingham Cardiovascular Risk	https://reference.medscape.com/calculator/framingham-cardiovascular-disease-risk
Reynolds Risk Score Can use if no diabetes Unique for use of family history	http://www.reynoldsriskscore.org/
Pooled Cohort Equation	http://clinicalc.com/Cardiology/ASCVD/PooledCohort.aspx?example
ACC/AHA Risk Calculator	http://tools.acc.org/ASCVD-Risk-Estimator/
MESA Risk Calculator With addition of Coronary Artery Calcium Score, for CAD-only risk	https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx

*Patients who have known CAD are already at high global risk and are not applicable to the calculators.²⁹⁻³³

Definitions of Coronary Artery Disease^{2, 3, 5, 34, 35}

- Percentage stenosis refers to the reduction in diameter stenosis when angiography is the method and refers to cross-sectional narrowing when IVUS (intravascular ultrasound) is the method of determination
- Coronary artery calcification is a marker of risk, as measured by Agatston score on coronary artery calcium imaging. Its incorporation into Global Risk can be achieved by using the MESA risk calculator.
- Ischemia-producing disease (also called hemodynamically or functionally significant disease, for which revascularization might be appropriate), generally implies at least one of the following:
 - Suggested by percentage diameter stenosis $\geq 70\%$ by angiography; intermediate lesions are 50 – 69%³⁶
 - For a left main artery, suggested by a percentage stenosis $\geq 50\%$ or minimum lumen cross-sectional area on IVUS ≤ 6 square mm^{3, 35, 37}
 - FFR (fractional flow reserve) ≤ 0.80 for a major vessel^{35, 37}
- FFR (fractional flow reserve) is the distal to proximal pressure ratio across a coronary lesion during maximal hyperemia induced by either intravenous or intracoronary adenosine. Less than or equal to 0.80 is considered a significant reduction in coronary flow

Anginal Equivalent^{3, 27, 38}

Development of an anginal equivalent (e.g., shortness of breath, fatigue, or weakness) either with or without prior coronary revascularization should be based upon the documentation of reasons to suspect that symptoms other than chest discomfort are not due to other organ systems (e.g., dyspnea due to lung disease, fatigue due to anemia). This may include respiratory rate, oximetry, lung exam, etc. (as well as d-dimer, chest CT(A), and/or PFTs, when appropriate), and then incorporated into the evaluation of coronary artery disease as would chest discomfort. Syncope per se is not an anginal equivalent.

Abbreviations

AAD	Antiarrhythmic drug
ADLs	Activities of daily living
BSA	Body surface area in square meters
CABG	Coronary artery bypass grafting surgery
CAC	Coronary artery calcium
CAD	Coronary artery disease
CCTA	Coronary computed tomography angiography
CMR	Cardiovascular magnetic resonance imaging
CT(A)	Computed tomography (angiography)
DTS	Duke Treadmill Score
ECG	Electrocardiogram
FFR	Fractional flow reserve
HCM	Hypertrophic cardiomyopathy
IVUS	Intravascular ultrasound
LBBB	Left bundle-branch block
LVEF	Left ventricular ejection fraction
LVH	Left ventricular hypertrophy
LVOT	Left ventricular outflow tract
MESA	Multi-Ethnic Study of Atherosclerosis
MET	Estimated metabolic equivalent of exercise
MI	Myocardial infarction
MPI	Myocardial perfusion imaging
MR	Mitral regurgitation
MS	Mitral stenosis
PCI	Percutaneous coronary intervention
PET	Positron emission tomography
PFT	Pulmonary function test
PVCs	Premature ventricular contractions
SE	Stress echocardiography
TTE	Transthoracic echocardiography
VT	Ventricular tachycardia
VF	Ventricular fibrillation
WPW	Wolff-Parkinson-White

REFERENCES

1. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. Feb 4 2014;63(4):380-406. doi:10.1016/j.jacc.2013.11.009
2. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. Oct 2013;34(38):2949-3003. doi:10.1093/eurheartj/eh296
3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. Dec 18 2012;126(25):e354-471. doi:10.1161/CIR.0b013e318277d6a0
4. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Cardiovasc Comput Tomogr*. Dec 01 2021;doi:10.1016/j.jcct.2021.11.009
5. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. May 2 2017;69(17):2212-2241. doi:10.1016/j.jacc.2017.02.001
6. Budoff MJ, Raggi P, Beller GA, et al. Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient: The Imaging Council of the American College of Cardiology. *JACC Cardiovasc Imaging*. Feb 2016;9(2):176-92. doi:10.1016/j.jcmg.2015.11.011
7. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome: results from a population-based survey. *Diabetes Care*. May 2003;26(5):1635.

8. Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Nucl Cardiol*. Aug 2019;26(4):1392-1413. doi:10.1007/s12350-019-01751-7
9. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Oct 2018;72(14):e91-e220. doi:10.1016/j.jacc.2017.10.054
10. Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. *Circ Arrhythm Electrophysiol*. Oct 2015;8(5):1048-56. doi:10.1161/circep.115.002856
11. Gräni C, Buechel RR, Kaufmann PA, Kwong RY. Multimodality Imaging in Individuals With Anomalous Coronary Arteries. *JACC Cardiovasc Imaging*. Apr 2017;10(4):471-481. doi:10.1016/j.jcmg.2017.02.004
12. Tang K, Wang L, Shi R, et al. The role of myocardial perfusion imaging in evaluating patients with myocardial bridging. *J Nucl Cardiol*. Feb 2011;18(1):117-22. doi:10.1007/s12350-010-9303-6
13. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. Apr 25 2017;135(17):e927-e999. doi:10.1161/cir.0000000000000484
14. Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging*. Aug 2013;14(8):721-40. doi:10.1093/ehjci/jet123
15. Bonow RO, O'Gara PT, Adams DH, et al. 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. May 5 2020;75(17):2236-2270. doi:10.1016/j.jacc.2020.02.005
16. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jun 10 2014;63(22):e57-185. doi:10.1016/j.jacc.2014.02.536
17. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. Sep 21 2017;38(36):2739-2791. doi:10.1093/eurheartj/ehx391

18. Steiner J, Rodés-Cabau J, Holmes DR, Jr., LeWinter MM, Dauerman HL. Mechanical Intervention for Aortic Valve Stenosis in Patients With Heart Failure and Reduced Ejection Fraction. *J Am Coll Cardiol*. Dec 19 2017;70(24):3026-3041. doi:10.1016/j.jacc.2017.10.040
19. Lancellotti P, Pellikka PA, Budts W, et al. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. Feb 2017;30(2):101-138. doi:10.1016/j.echo.2016.10.016
20. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Dec 22 2020;76(25):3022-3055. doi:10.1016/j.jacc.2020.08.044
21. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol*. Dec 9 2014;64(22):e77-137. doi:10.1016/j.jacc.2014.07.944
22. Patel AY, Eagle KA, Vaishnava P. Cardiac risk of noncardiac surgery. *J Am Coll Cardiol*. Nov 10 2015;66(19):2140-2148. doi:10.1016/j.jacc.2015.09.026
23. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur Heart J*. Sep 14 2014;35(35):2383-431. doi:10.1093/eurheartj/ehu282
24. Velasco A, Reyes E, Hage FG. Guidelines in review: Comparison of the 2014 ACC/AHA guidelines on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery and the 2014 ESC/ESA guidelines on noncardiac surgery: Cardiovascular assessment and management. *J Nucl Cardiol*. 02 2017;24(1):165-170. doi:10.1007/s12350-016-0643-8
25. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. *J Am Coll Cardiol*. Jul 31 2012;60(5):434-80. doi:10.1016/j.jacc.2012.05.008
26. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. *J Nucl Cardiol*. Jun 2016;23(3):606-39. doi:10.1007/s12350-015-0387-x
27. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Aug 1 2017;70(5):620-663. doi:10.1016/j.jacc.2017.03.002

28. Mark DB, Hlatky MA, Harrell FE, Jr., Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med.* Jun 1987;106(6):793-800. doi:10.7326/0003-4819-106-6-793
29. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* Sep 10 2019;74(10):e177-e232. doi:10.1016/j.jacc.2019.03.010
30. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation.* Feb 12 2008;117(6):743-53. doi:10.1161/circulationaha.107.699579
31. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* Jul 1 2014;63(25 Pt B):2935-2959. doi:10.1016/j.jacc.2013.11.005
32. McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). *J Am Coll Cardiol.* Oct 13 2015;66(15):1643-53. doi:10.1016/j.jacc.2015.08.035
33. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *Jama.* Feb 14 2007;297(6):611-9. doi:10.1001/jama.297.6.611
34. Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory. *J Am Coll Cardiol.* Feb 27 2007;49(8):839-48. doi:10.1016/j.jacc.2006.10.055
35. Mintz G. IVUS in PCI Guidance. American College of Cardiology. Updated June 13, 2016. Accessed January 27, 2023. <https://www.acc.org/latest-in-cardiology/articles/2016/06/13/10/01/ivus-in-pci-guidance>
36. Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, Society of Thoracic Surgeons. *J Thorac Cardiovasc Surg.* Jul 2012;144(1):39-71. doi:10.1016/j.jtcvs.2012.04.013
37. Lotfi A, Davies JE, Fearon WF, Grines CL, Kern MJ, Klein LW. Focused update of expert consensus statement: Use of invasive assessments of coronary physiology and structure: A position statement of the society of cardiac angiography and interventions. *Catheter Cardiovasc Interv.* Aug 1 2018;92(2):336-347. doi:10.1002/ccd.27672

38. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). *Eur Heart J*. Nov 2009;30(21):2631-71. doi:10.1093/eurheartj/ehp298

POLICY HISTORY

Date	Summary
May 2023	<ul style="list-style-type: none"> • Removed time limitation “within past two years” for further evaluation inconclusive prior CAD evaluation • Added coronary stenosis of unclear significance on coronary angiography • Added evaluation of asymptomatic moderate or severe aortic stenosis (AS) and aortic regurgitation (AR) for measurement of changes in valve hemodynamics • Added evaluation symptomatic patients with suspected diastolic dysfunction • Added statement on clinical indications not addressed in this guideline
February 2022	<ul style="list-style-type: none"> • Moved the sentence regarding utilization of suitable alternatives such as Stress Echocardiography and MPI to the General Information section • Clarified “intermediate lesions are 50-69%” for ischemia-producing disease • Placed Link to Overview Section in General Information • Deleted the requirement for diabetes when calcium score > 400 for stress imaging • Added Calcium score section: <ul style="list-style-type: none"> ○ Added stress imaging approval for calcium score > 100 with symptoms consistent with low to intermediate pretest probability • Changed preoperative guideline to include intermediate risk surgery with one or more risk factors AND documentation of an inability to walk (or <4 METs) AND there has not been an imaging stress test within 1 year • Changed solid organ transplant guideline to include stem cell transplant and “any” organ transplant • Added definition of surgical risk to preop guidelines • In Background section clarified the requirement for description of chest pain by adding sentence “The medical record should provide enough detail to establish the type of chest pain. “ • Added definition of Q waves • Deleted sentence regarding calcium scoring within the Global Risk Section • Deleted sentence regarding using calcium score solely for risk stratification • Deleted IFR references

Reviewed / Approved by Clinical Guideline Committee

Disclaimer: *Evolut Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Evolut uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolut Clinical Guidelines. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolut reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. **Members should contact their Plan customer service representative for specific coverage information.***